Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 19% of the time (731 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: randomizationsubjects withdiagnosisevidencemri
  Phrases that lowered it: and safetythe studyevaluatesafety ofefficacy and
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Minimum age: 50 (raises risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 11.8% (lowers risk) · Drug's FDA history
• Maximum age: 90 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: not given (raises risk) · Design
• Sponsor's past trials: 3 (lowers risk) · Sponsor's track record
• Keywords listed: 0 (raises risk) · Design
• Blinding: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 4 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 69.7% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil NCT00672945 · started 2008 · scored riskier than 79% of active trials terminated
• A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation NCT05318976 · started 2022 · scored riskier than 67% of active trials completed
• Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease NCT03625622 · started 2019 · scored riskier than 68% of active trials completed
• A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease NCT01513967 · started 2012 · scored riskier than 28% of active trials completed
• Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease NCT02389413 · started 2015 · scored riskier than 59% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.